<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03252925</url>
  </required_header>
  <id_info>
    <org_study_id>SOOCHOW-HY-2017</org_study_id>
    <nct_id>NCT03252925</nct_id>
  </id_info>
  <brief_title>A Safety and Efficacy Study of NAC in Patients With TA-TMA</brief_title>
  <official_title>A Safety and Efficacy Study of N-acetylcysteine in Patients With Hematopoietic Stem Cell Transplantation Associated Thrombotic Microangiopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The First Affiliated Hospital of Soochow University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      HSCT associated thrombotic microangiopathy(TA-TMA) is a heterogeneous, fatal disorder seen
      within 100 days post-transplant and presents with thrombocytopenia, hemolysis, acute renal
      failure, mental status changes and involvement of other organs. N-Acetylcysteine (NAC) is a
      small, simple molecule that began as a generic drug almost 40 years ago. It has since been
      approved by the FDA for many indications. The investigators conducted an prospective clinical
      trial to evaluate the safety and efficiency of NAC in patients with TA-TMA.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hematopoietic stem cell transplantation (HSCT) has been commonly used as a potentially
      curative option in the treatment of various hematological malignancies. However, it may end
      up with serious complications in various systems, including the hemostatic system. HSCT
      associated thrombotic microangiopathy(TA-TMA) is a heterogeneous, fatal disorder seen within
      100 days post-transplant and presents with thrombocytopenia, hemolysis, acute renal failure,
      mental status changes and involvement of other organs. Since the pathophysiology has not been
      clarified, there are no established treatments for TA-TMA several agents seem to have
      successful results. N-Acetylcysteine (NAC) is a small, simple molecule that began as a
      generic drug almost 40 years ago. It has since been approved by the FDA for many indications.
      Studies showed NAC reduce plasma VWF multimers and VWF multimeric size without an effect on
      the bleeding time in vitro and in vivo, thus proposed as a possible supplementary treatment
      for TTP. The investigators conducted an prospective clinical trial to evaluate the safety and
      efficiency of NAC in patients with TA-TMA.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2017</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of TA-TMA.</measure>
    <time_frame>100 days</time_frame>
    <description>The incidence of TMA after HSCT.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The level of VWF multimers</measure>
    <time_frame>100 days</time_frame>
    <description>The level of VWF multimers in patients post HSCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The level of endothelial micro particle</measure>
    <time_frame>100 days</time_frame>
    <description>The level of endothelial micro particle in patients post HSCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The level of TNF-α</measure>
    <time_frame>100 days</time_frame>
    <description>The level of TNF-α in patients post HSCT.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The level of ROS</measure>
    <time_frame>100 days</time_frame>
    <description>The level of ROS in patients post HSCT.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Thrombotic Microangiopathies</condition>
  <arm_group>
    <arm_group_label>Experimental Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>N-Acetylcysteine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo Oral Tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-Acetylcysteine</intervention_name>
    <description>50mg/Kg.d, oral</description>
    <arm_group_label>Experimental Group</arm_group_label>
    <other_name>NAC</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>50mg/Kg.d, oral</description>
    <arm_group_label>Control Group</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients be scheduled to undergo HSCT;

          2. Not received decitabine 6 month ago;

          3. Without severe organ damage;

          4. ECOG 0-2;

          5. Informed consent were obtained.

        Exclusion Criteria:

          1. Be sensitive to NAC;

          2. Bronchial asthma；

          3. Peptic ulcer；

          4. Severe organ damage；

          5. Pregnancy and breastfeeding women；
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Depei Wu, MD. PhD.</last_name>
    <role>Study Chair</role>
    <affiliation>The First Affiliated Hospital of Soochow University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yue Han, MD. PhD.</last_name>
    <phone>0512-67781856</phone>
    <email>hanyue@suda.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Depei Wu, MD. PhD.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The First affiliated Hospital of SooChow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiang Zhang, MD</last_name>
      <phone>0512-67781856</phone>
      <email>zhuxiaomin@suda.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>George JN, López JA, Konkle BA. N-Acetylcysteine: an old drug, a new insight, a potentially effective treatment for thrombotic thrombocytopenic purpura. Transfusion. 2014 May;54(5):1205-7. doi: 10.1111/trf.12561.</citation>
    <PMID>24819072</PMID>
  </reference>
  <reference>
    <citation>Tersteeg C, Roodt J, Van Rensburg WJ, Dekimpe C, Vandeputte N, Pareyn I, Vandenbulcke A, Plaimauer B, Lamprecht S, Deckmyn H, Lopez JA, De Meyer SF, Vanhoorelbeke K. N-acetylcysteine in preclinical mouse and baboon models of thrombotic thrombocytopenic purpura. Blood. 2017 Feb 23;129(8):1030-1038. doi: 10.1182/blood-2016-09-738856. Epub 2016 Dec 23.</citation>
    <PMID>28011677</PMID>
  </reference>
  <reference>
    <citation>Acedillo RR, Govind M, Kashgary A, Clark WF. Treatment of severe, refractory and rapidly evolving thrombotic thrombocytopenic purpura. BMJ Case Rep. 2016 Jun 9;2016. pii: bcr2016215491. doi: 10.1136/bcr-2016-215491.</citation>
    <PMID>27284100</PMID>
  </reference>
  <reference>
    <citation>Rottenstreich A, Hochberg-Klein S, Rund D, Kalish Y. The role of N-acetylcysteine in the treatment of thrombotic thrombocytopenic purpura. J Thromb Thrombolysis. 2016 May;41(4):678-83. doi: 10.1007/s11239-015-1259-6.</citation>
    <PMID>26245827</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 22, 2017</study_first_submitted>
  <study_first_submitted_qc>August 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2017</study_first_posted>
  <last_update_submitted>August 16, 2017</last_update_submitted>
  <last_update_submitted_qc>August 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Diseases</mesh_term>
    <mesh_term>Thrombotic Microangiopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetylcysteine</mesh_term>
    <mesh_term>N-monoacetylcystine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

